research Taxane-Induced Alopecia: A Historical Review of Patients With Ovarian or Breast Cancer Treated With Paclitaxel, Docetaxel, or Paclitaxel Poliglumex
PPX causes much less hair loss than traditional taxanes.
Search
forLearn
0 / 0 results — no results
Research
5 / 521 resultsresearch Phase II Trial of Paclitaxel Poliglumex (CT-2103) in Pre- and Post-Menopausal Women on Hormonal Replacement Therapy with Non-Small Cell Lung Cancer
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Persistent Major Alopecia Following Adjuvant Docetaxel for Breast Cancer: Incidence, Characteristics, and Prevention with Scalp Cooling
Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
research Nanoparticles in Cancer Treatment: A Narrative Review
Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Premenopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
Community Join
0 / 0 results — no results